Logo
x

Search

Subscribe Now

vicore

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

Vicore Highlights the P-IIa (AIR) Study Data of Buloxibutid for the Treatment of Idiopathic Pulmonary Fibrosis at ATS 2024

  • May 20, 2024
Vicore’s Almee Receives the US FDA’s Breakthrough Device Designation for Pulmonary Fibrosis

Vicore’s Almee Receives the US FDA’s Breakthrough Device Designation for Pulmonary Fibrosis

  • March 19, 2024
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.